Edition:
United Kingdom

People: Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

41.51USD
7:07pm BST
Change (% chg)

$-1.18 (-2.76%)
Prev Close
$42.69
Open
$42.69
Day's High
$42.72
Day's Low
$41.49
Volume
381,300
Avg. Vol
1,868,413
52-wk High
$43.65
52-wk Low
$31.57

Ballinger, Kevin 

Mr. Kevin J. Ballinger is Executive Vice President and Global President - Interventional Cardiology of the Company. He is our executive vice president and global president, Interventional Cardiology, a position he has held since March 2017. In his current role, Mr. Ballinger is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. Prior to that, he served as senior vice president from January 2013 to February 2017. Mr. Ballinger has more than 20 years of interventional cardiology experience. Prior to his current role, he was also president, interventional cardiology and held a variety of engineering and general management positions within our Interventional Cardiology and Peripheral Interventions business units, including vice president and general manager, group program management, cardiology, rhythm and vascular; vice president of research and development, peripheral interventions and vice president of program management, cardiovascular. Mr. Ballinger earned a B.S. in mechanical engineering from Michigan Technological University and an M.B.A. from the University of Minnesota.

Basic Compensation

Total Annual Compensation, USD 1,016,280
Restricted Stock Award, USD 1,337,620
Long-Term Incentive Plans, USD --
All Other, USD 487,584
Fiscal Year Total, USD 2,841,490

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 146,347 3,900,240.00
Name Fiscal Year Total

Michael Mahoney

13,970,900

Daniel Brennan

3,665,820

Kevin Ballinger

2,841,490

Joseph Fitzgerald

4,036,320

Edward Mackey

3,818,020

Ian Meredith

--
As Of  31 Dec 2018